Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

New Clinical Alert Issued

New Clinical Alert Issued. NLM Technical Bulletin. 2005 Jan–Feb;(342):e1.

January 04, 2005 [posted]

The National Institute on Aging (NIA) has issued a new Clinical Alert on December 20, 2004:

The National Institutes of Health (NIH) announced that research investigators suspended, until further notice, the use of two drugs, naproxen (220 mg twice a day) and celecoxib (200 mg twice a day), in a large, three-arm, national Alzheimer's disease prevention trial sponsored by the National Institute on Aging (NIA), a part of the NIH. The trial, called the Alzheimer's Disease Anti-Inflammatory Prevention Trial (or ADAPT) was designed to assess the potential benefit of long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) - naproxen (Aleve™) and the COX-2 inhibitor celecoxib (Celebrex™) in decreasing the risk of developing Alzheimer's Disease in people 70 years of age or older who were considered to be at increased risk because of family history, but did not have symptoms of the disease.

Links to Clinical Alerts can also be found from these NLM Web sites:

  • MedlinePlus features Clinical Alerts as NIH Press Releases on the appropriate Health Topics page(s).
  • As before, PubMed and the NLM Gateway have a link to the Clinical Alerts on their side bars. In addition, a featured link will now be available from their Home Page for ten days after a new alert is issued.